extensive-stage small cell lung cancer
Conditions
Interventions
PCI group:prophylactic cranial irradiation
control group:none
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Pathological or cytological diagnosis of stage IV small cell lung cancer (by using AJCC 7th edition staging criteria); 1-3 extra-cranial metastatic organs before chemotherapy; Chemotherapy with CE (etoposide + carboplatin) or EP (etoposide + cisplatin) regimen for 4 ~ 6 cycles, and patients with complete remission or partial remission (more than 1 site) after chemotherapy; There was no progression of tumor lesions after chemotherapy; There was no abnormality of degree II or above in blood indicators after chemotherapy (including blood routine and liver and kidney function, according to CTCAE 4.0 criteria); Aged from 18 to 65 years, kps score = 70; They agree to participate in the study and may independently sign the informed consent form; the estimated survival time = 3 months; There was no serious medical disease or major organ dysfunction.
Exclusion criteria
Exclusion criteria: Patients with brain or nervous system metastases; Presence of serious or acute comorbidities; Patients who are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative incidence of brain metastases over 2 years;2 years of progression-free survival;score of Hopkins Verbal Learning Test;side effects of treatment;failure type;Exploratory biomarker analysis (detection of CTC, ctDNA and microRNA); | — |
Countries
China
Contacts
Public ContactZhou Zongmei
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed